Malignant Skin Lesions Viva

Long Case Viva Defence

Opening statement

"This patient presents with a problem best framed as Malignant Skin Lesions. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]

Examiner questions

Q1: "What makes this urgent?" [1]

"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]

Q2: "What is your first investigation package?" [2]

"I order tests that change management now, not a scattergun panel." [1] [2]

Q3: "Walk me through treatment." [1]

"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]

Q4: "What is the classic trap?" [2]

"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]

Short case

Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]

References

[1]Jones LS, McEldrew E, Bartus CL Review of Skin Depigmentation Practices and Cutaneous Malignancy J Clin Aesthet Dermatol, 2026.PMID 42459248
[2]Alheggi A Artificial Intelligence in Inherited Epidermolysis Bullosa: Current Evidence, Challenges, and Future Directions Diagnostics (Basel), 2026.PMID 42449804
[3]Ondrušová L, Kreisingerová K, Vachtenheim J MITF Is an Essential and Functionally Multifaceted Transcription Factor in Cutaneous Melanoma Cancers (Basel), 2026.PMID 42449703
[4]Erdem S, Amparore D, Re C, Verep S, et al. What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group World J Urol, 2026.PMID 42373875
[5]Leru PM, Anton VF, Georgescu DG Severe Persistent Hypereosinophilia of Undetermined Significance: Diagnostic Challenges in Clinical Practice and Two-Year Follow-Up Rom J Intern Med, 2026.PMID 42335361
[6]Nicer J, Kania J, Sobol M, Jurkiewicz D, et al. Impact of Anatomical Subsite on Achieved Surgical Margins in Head and Neck Basal Cell Carcinoma Otolaryngol Pol, 2025.PMID 42138045
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

Long Case Viva Defence

Opening statement

Examiner questions

Q1: "What makes this urgent?" [1]

"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]

Q2: "What is your first investigation package?" [2]

"I order tests that change management now, not a scattergun panel." [1] [2]

Q3: "Walk me through treatment." [1]

"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]

Q4: "What is the classic trap?" [2]

"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]

Short case

Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]

References

[1]Jones LS, McEldrew E, Bartus CL Review of Skin Depigmentation Practices and Cutaneous Malignancy J Clin Aesthet Dermatol, 2026.PMID 42459248
[2]Alheggi A Artificial Intelligence in Inherited Epidermolysis Bullosa: Current Evidence, Challenges, and Future Directions Diagnostics (Basel), 2026.PMID 42449804
[3]Ondrušová L, Kreisingerová K, Vachtenheim J MITF Is an Essential and Functionally Multifaceted Transcription Factor in Cutaneous Melanoma Cancers (Basel), 2026.PMID 42449703
[4]Erdem S, Amparore D, Re C, Verep S, et al. What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group World J Urol, 2026.PMID 42373875
[5]Leru PM, Anton VF, Georgescu DG Severe Persistent Hypereosinophilia of Undetermined Significance: Diagnostic Challenges in Clinical Practice and Two-Year Follow-Up Rom J Intern Med, 2026.PMID 42335361
[6]Nicer J, Kania J, Sobol M, Jurkiewicz D, et al. Impact of Anatomical Subsite on Achieved Surgical Margins in Head and Neck Basal Cell Carcinoma Otolaryngol Pol, 2025.PMID 42138045
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

Malignant Skin Lesions — Viva Defence

Malignant Skin Lesions Viva

Long Case Viva Defence

Opening statement

Examiner questions

Short case

References

Malignant Skin Lesions — Viva Defence

Malignant Skin Lesions Viva

Long Case Viva Defence

Opening statement

Examiner questions

Short case

References